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Abstract
Transcriptome imputation has become a popular method for integrating genotype data with publicly available expression
data to investigate the potentially causal role of genes in complex traits. Here, we compare three approaches (PrediXcan,
MetaXcan and FUSION) via application to genome-wide association study (GWAS) data for Crohn’s disease and type 1
diabetes from the Wellcome Trust Case Control Consortium. We investigate: (i) how the results of each approach compare
with each other and with those of standard GWAS analysis; and (ii) how variants in the models used by the prediction tools
compare with variants previously reported as eQTLs. We find that all approaches produce highly correlated results when
applied to the same GWAS data, although for a subset of genes, mostly in the major histocompatibility complex, the
approaches strongly disagree. We also observe that most associations detected by these methods occur near known GWAS
risk loci. PrediXcan and MetaXcan’s models for predicting expression more consistently recapitulate known effects of
genotype on expression, suggesting they are more robust than FUSION. Application of these transcriptome imputation
approaches to summary statistics from meta-analyses in Crohn’s disease and type 1 diabetes detects 53 significant expression
—Crohn’s disease associations and 154 significant expression—type 1 diabetes associations, providing insight into biology
underlying these diseases. We conclude that while current implementations of transcriptome imputation typically detect
fewer associations than GWAS, they nonetheless provide an interesting way of interpreting association signals to identify
potentially causal genes, and that PrediXcan and MetaXcan generally produce more reliable results than FUSION.
Introduction
Genome-wide association studies (GWAS) have been
successful at finding regions of the genome associated
with a range of phenotypes—over 50,000 unique asso-
ciations across more than 3200 traits are listed in the
NHGRI-EBI GWAS catalogue [1] as of February 2018.
However, the causal genes and biological mechanisms
underlying these associations often remain unclear [2].
SNPs driving association signals in GWAS risk loci tend
to fall within regulatory regions of genes, and are enriched
for expression quantitative trait loci (eQTLs) [3], sug-
gesting a key role of genetically regulated gene expression
in complex human traits. Indeed, this has been confirmed
through the use of methods examining the co-localisation
of SNPs at GWAS loci and expression signals [4, 5].
However, these methods are unlikely to capture the full
signal of genetically regulated gene expression as they
often focus on single SNPs/eQTLs instead of all SNPs near
to a gene, and they may fail to detect small effect sizes of
expression on a trait.
A recent approach to detecting effects of gene
expression on traits by integrating genotype and expres-
sion data, known as transcriptome imputation, has been
developed and implemented in the software packages
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PrediXcan [6], MetaXcan (an extension of PrediXcan) [7]
and FUSION [8]. These methods have been used to
identify potential expression associations with a number
of traits, including schizophrenia, type 2 diabetes and
autoimmune vitiligo [9–12]. A typical transcriptome
imputation analysis consists of two steps. First, pre-
viously gathered resources where genotype and expres-
sion measurements have been taken from the same
individuals, such as the Genotype-Tissue Expres-
sion (GTEx) Consortium [13], are used to construct
models that predict values for the genetically regulated
portion of gene expression from genotype data. Second,
these predictive models are applied to data where both
genotype and phenotype measurements have been gath-
ered (individual-level data or summary statistics from
GWAS) to impute expression values and test the asso-
ciation of expression values with the phenotype of
interest. This approach has some conceptual similarity
with two-sample Mendelian randomisation [14] for inte-
grating genotype and expression data. It also offers a
more direct test of the effect of gene expression on a
phenotype than that performed by co-localisation meth-
ods such as coloc [4]. Crucially, by using resources, such
as GTEx, where expression data have been gathered for
multiple tissues, tissue-specific expression prediction
models for tissues relevant to the phenotype of interest
can be used.
Implementations of transcriptome imputation approa-
ches have a number of methodological differences, such
as the way the predictive models are built, and whether
individual-level genotype data (as with PrediXcan) or
summary statistics from GWAS (as with MetaXcan and
FUSION) are used to perform the imputation and evaluate
association with phenotype. Here, we compare tran-
scriptome imputation methods by applying each of them
to GWAS data from the Wellcome Trust Case Control
Consortium (WTCCC1) study [15], focusing on Crohn’s
disease (CD) and type 1 diabetes (T1D), and then com-
paring the results obtained. We also investigate the gene
expression prediction models used by the different
methods to understand better the differences between
them. By using prediction models constructed using gene
expression measures from the GTEx Consortium, we also
compare how these methods perform when predicting
expression-trait associations across a range of tissues
relevant to each phenotype. As these methods have
similarities to GWAS, we consider how they perform in
comparison to standard GWAS analysis of the WTCCC1
data. Finally, we apply MetaXcan to summary statistics
from recent larger meta-analyses of CD [16] and T1D [17]
to find novel predicted expression-trait associations and to
improve understanding of the biological mechanisms
underpinning these diseases.
Materials and methods
WTCCC1 case–control data sets
The initial case/control data sets from WTCCC1 that we
analysed corresponded to the same data sets used by
Gamazon et al. [6]. These data consisted of 1748 CD cases,
1963 T1D cases and 2938 shared controls [15]. SNPs and
samples that failed the WTCCC1-automated quality-control
(QC) procedures, SNPs with MAF <0.01 and SNPs with
abnormal cluster plots were removed. The remaining SNPs
and samples were taken forward for genome-wide imputa-
tion. We followed the same genotype imputation procedure
as Gamazon et al. [6], using the Michigan Imputation server
[18], with the 1000Genomes phase 1 v3 reference panel
(all ethnicities) and ShapeIT phasing. For each disease,
we imputed cases and controls together. Following impu-
tation, we removed SNPs with imputation R2 < 0.8 and
MAF <0.01.
Transcriptomic imputation-based methods
All transcriptome imputation-based methods examined here
attempt to find potential gene expression-trait associations by
predicting values for the genetically regulated portion of gene
expression from SNP data, and then regressing predicted
expression on the phenotype of interest. A typical analysis
using these methods is performed in two steps. The first is the
training of the gene expression prediction models in data sets
where both genotype and gene expression data are available
for the same individuals. This step has been performed by the
developers of each method, and the resulting prediction
models have been made available online. These models can
be downloaded and applied to genotype data or GWAS
summary statistics to impute gene expression-trait associa-
tions. PrediXcan and MetaXcan prediction models are avail-
able at http://predictdb.hakyimlab.org/, and the FUSION
prediction models are available at http://gusevlab.org/projects/
fusion/. Key differences between the software packages are
described in Supplementary Table S1.
Application of transcriptomic imputation methods
We applied PrediXcan [6] to the imputed WTCCC1 CD and
T1D SNP data. When attempting to recreate the results of
Gamazon et al. [6], we followed their analytical pipeline by
using the subset of SNPs present in HapMap2 and gene
expression prediction models trained in depression genes
and networks (DGN) whole blood.
For comparative analyses between PrediXcan, MetaXcan
and FUSION, we used the full set of imputed SNPs passing
QC. For the analysis of CD, we applied prediction models
for the following GTEx tissues: whole blood, Epstein–Barr
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virus (EBV)-transformed lymphocytes and sigmoid colon.
For the analysis of T1D, we applied prediction models for
the following GTEx tissues: whole blood, EBV-transformed
lymphocytes and pancreas. eQTLs for these tissues (or
similar tissues) have previously been used to investigate the
role of gene expression in these phenotypes [5, 19, 20]. As
MetaXcan and FUSION use summary statistics instead of
individual-level genotype data, we performed GWAS on the
imputed CD and T1D data using logistic regression
implemented through SNPTEST [21]. We did not adjust for
covariates. Association z scores were then used as input for
MetaXcan and FUSION, as recommended by the software
developers.
eQTL data and comparisons
eQTL data for GTEx tissues analysed here were down-
loaded from the GTEx portal on 7 February 2017. For
comparisons with gene expression predictive models from
transcriptome imputation methods, we used eQTL data
from the GTEx release that each set of models was based on
—release V6p for PrediXcan/MetaXcan predictive models
and V6 for FUSION predictive models. For each model, we
calculated a measure of agreement between the eQTL data
and the gene expression prediction model, Aeqtl, which we
defined as the percentage of SNPs present in both eQTL
data and the predictive model and for which the direction of
effect was the same in both of these.
Geuvadis data and comparisons
Genotype and expression data for 465 individuals were
obtained from the Geuvadis Project [22]. Genotypes were
measured as part of the 1000 Genomes Project, and
expression measurements were gathered via RNA-seq, then
underwent quantile and PEER factor normalisation. We
removed SNPs with MAF <0.01 or with imputation R2 <
0.8. We also removed African samples as their expression
measures were markedly different to those of European
samples, leaving genotype and expression data for 373
individuals. PrediXcan and FUSION models were applied
to the genotype data to predict expression values, and cor-
relation between these predicted expression values and the
measured expression value was examined.
Application of MetaXcan to published summary
statistics
MetaXcan was applied to summary statistics from a recently
published CD meta-analysis [16]. We used summary sta-
tistics from the meta-analysis of seven CD GWAS con-
ducted as part of this study, but did not apply MetaXcan to
the larger set of summary statistics as this included studies
based on the Immunochip. Prediction models trained in
1000 Genomes data for the following GTEx tissues were
used: whole blood, EBV-transformed lymphocytes and
sigmoid colon.
We also applied MetaXcan to summary statistics from a
recently published T1D meta-analysis [17]. We applied
MetaXcan using prediction models trained in 1000 Gen-
omes data for the following GTEx tissues: whole blood,
EBV-transformed lymphocytes and pancreas.
Results
Replication of original PrediXcan results
As a proof of principle, we first aimed to recreate the find-
ings of Gamazon et al. [6], by applying prediction models
trained in DGN whole blood to the HapMap subset of SNPs
from our imputed WTCCC1 CD and T1D data. Results are
displayed in Supplementary Figure S1 and listed in Sup-
plementary Table S2. Of the eight genes significantly asso-
ciated with CD in Gamazon et al. [6], seven were significant
in our results (Bonferroni corrected, p < 5.61 × 10−6), while
BSN just missed significance (p= 1.10 × 10−5). Results were
also similar for T1D, with 24 of 29 significant results in
Gamazon et al. [6] achieving significance here. We found a
much stronger peak of association in the MHC locus on
chromosome 6 than Gamazon et al. [6] (most significant p in
Gamazon et al. [6]= 2.92 × 10−13; most significant p in our
results= 9.81 × 10−71), consistent with many T1D GWAS
[15, 23]. We believe this difference likely occurred due to
updates to the DGN prediction models between the appli-
cation by Gamazon et al. [6] and our application here.
Comparison of transcriptomic imputation-based
methods
To compare how the different transcriptome imputation
methods perform, we next applied PrediXcan, MetaXcan
and FUSION to the imputed WTCCC1 CD and T1D data.
For each method we applied predictive models trained in
whole blood data from the GTEx Consortium [13], using
the complete set of 1000 Genomes phase 1 imputed SNPs
from the WTCCC1 data.
The different approaches produced broadly similar sets
of results when applied to the CD data (Fig. 1a). Both
PrediXcan and MetaXcan found significant associations on
chromosomes 3 (C3orf62), 5 (SLC22A5 and IRGM) and 17
(PGS1), while FUSION found associations approaching
significance on chromosomes 3 (UBA7 in a similar position
to C3orf62) and 5 (SLC22A5). IRGM, PGS1 and C3orf62
were not tested by FUSION, likely because each method
used different criteria to determine the genes for which
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prediction models were built (Supplementary Table S1).
Closer examination revealed that most differences between
approaches’ results occurred because they tested different
genes. For whole blood, PrediXcan and MetaXcan tested
more genes (6105 genes) than FUSION did (2058 genes). In
total, 1426 genes were tested by every method, representing
a set of genes where direct comparison could be made.
Likewise, each method produced similar results when
applied to the T1D data (Fig. 1b). All methods found sig-
nificant associations at the MHC on chromosome 6, and on
chromosome 12 (RPS26 and SUOX). Again, many differ-
ences between the methods’ results could be explained by
whether a gene was or was not tested. For example, pre-
dicted CLEC16A expression was found to be significantly
associated with T1D by PrediXcan and MetaXcan, but was
not tested by FUSION. Similarly, each method produced a
strong peak of association at the MHC, but comprising of
different genes—CYP21A2 was found to be associated with
T1D by PrediXcan (p= 3.26 × 10−75) and MetaXcan (p=
2.54 × 10−93), but was not tested by FUSION. In total, 23
MHC genes found to be significant by PrediXcan and
MetaXcan were not tested by FUSION.
We quantified the agreement between the different
methods’ results, finding that z scores from the different
methods were highly correlated (Fig. 2). As expected,
PrediXcan and MetaXcan results showed the greatest cor-
relation. Results from FUSION were also highly correlated
with both PrediXcan and MetaXcan results, underlining the
similarities between transcriptome imputation approaches.
For a number of genes, the methods produced notably
different results, with PrediXcan/MetaXcan predicting dif-
ferent directions of effect of expression on phenotype
Fig. 1 Comparison of results from applications of three transcriptome
imputation methods to imputed WTCCC1 a CD data and b T1D data.
Manhattan plots showing p values of predicted expression-trait asso-
ciations from applications of PrediXcan, MetaXcan and FUSION to
imputed WTCCC1 a CD data and b T1D data using prediction models
trained in GTEx whole blood data. P values are plotted against the
transcription start site for each gene. The red line on each plot shows
the Bonferroni-corrected significance threshold at 7.44 × 10−6
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compared to FUSION for 249 unique CD associations and
246 T1D associations. We determined the pairwise differ-
ence in z scores produced by each method for the 1426
genes analysed by every method, finding that all large dif-
ferences in z scores between methods were between either
PrediXcan and FUSION or MetaXcan and FUSION.
Table 1 highlights genes showing large differences in z
scores, where the methods disagreed the most about the
effect of gene expression on the trait of interest. These
differences are likely due to methodological differences
between the different software packages (see Supplemen-
tary Table S1).
To examine how well informed the gene expression
imputation was for genes showing a large difference
between their z scores achieved by the different software
packages, we sorted the 1426 genes by the difference
between their MetaXcan z score and FUSION z score.
These genes were split into ten equally sized bins, with the
10% of genes with smallest differences in z scores in bin 1
and the 10% of genes with largest z score differences in bin
10. For each bin, the mean percentage of each PrediXcan/
MetaXcan prediction model’s SNPs that were present in our
post-QC GWAS data was calculated. PrediXcan/MetaXcan
models in upper bins consistently had fewer of their mod-
els’ SNPs present in the GWAS data than PrediXcan/
MetaXcan models for genes in lower bins (Supplementary
Figures S2a and S2b). Interestingly, bin 10 showed a greater
proportion of genes from the MHC on chromosome 6 than
would be expected if bins were drawn randomly in both CD
and T1D analyses (Supplementary Figures S3a and S3b).
To determine which method’s models best matched their
expression training data, we next compared each model’s
SNPs with eQTL statistics from the same GTEx data that
were used to construct them. We hypothesised that pre-
dictive models would likely contain SNPs identified as
eQTLs, and that these SNPs would show the same direction
of effect on expression in the eQTL statistics as in the pre-
diction models. This seemed likely as predictive models
were based on a linear additive genetic model, so were
unlikely to capture complex relationships such as SNP–SNP
interactions. We tested each of the predictive models used by
PrediXcan, MetaXcan and FUSION by calculating a mea-
sure of agreement between the model and eQTL data that we
term Aeqtl (see 'Methods'). Supplementary Figure S4a shows
Fig. 2 Pairwise correlations between results of transcriptome imputa-
tion methods for WTCCC1 CD data. Pairwise Pearson correlations
between z scores produced by PrediXcan, MetaXcan and FUSION
from applications to a imputed WTCCC1 CD data and b imputed
WTCCC1 T1D data for the 1426 genes tested by all methods. Upper
panels show correlation values, lower panels show scatter plots of z
scores
Table 1 Genes showing the
three largest differences in
MetaXcan z score and FUSION
z score for each phenotype
Gene Phenotype PrediXcan z score MetaXcan z score FUSION z score
GTF2H2C Crohn’s disease −2.664 −2.74 1.483
TAP2 Crohn’s disease 3.011 2.961 −0.506
PLD2 Crohn’s disease 2.177 2.168 −0.87
HLA-DQA1 Type 1 diabetes 7.801 7.044 −17.338
HLA-DQB1 Type 1 diabetes −2.961 −2.923 −21.825
HLA-DRB1 Type 1 diabetes −7.735 −8.102 −20.594
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the distribution of this statistic for each GTEx whole blood
prediction model from PrediXcan/MetaXcan and FUSION.
Prediction models for PrediXcan and MetaXcan always
showed an Aeqtl of 1, indicating that every SNP had
a direction of effect consistent with the eQTL data, whereas
FUSION models showed a range of Aeqtl values (mean
Aeqtl= 0.68), indicating different levels of eQTL agreement
for different FUSION prediction models.
As a further comparison between methods, we applied
PrediXcan and FUSION models to genotype data from the
Geuvadis project to predict expression, and examined the
correlation between predicted and measured expression
levels. Overall, there were 643 genes for which both Pre-
diXcan and FUSION predicted expression, and for which
expression was also measured in Geuvadis. For these 643
genes, the prediction R2 values (i.e., the mean squared
correlation coefficient between predicted and observed
expression) obtained from PrediXcan and FUSION were
found to be highly correlated (Supplementary Figure S5)
although the actual values of R2 achieved were quite vari-
able, with low values of R2 indicating limited predictive
ability for many genes. However, R2 was marginally greater
for predictions made with PrediXcan models (mean R2=
0.061, SE= 0.004) than for predictions with FUSION
models (mean R2= 0.050, SE= 0.004) (Supplementary
Figure S5), implying that PrediXcan/MetaXcan models
predict expression slightly more accurately.
Comparison of prediction models trained
in different tissues
Each transcriptome imputation approach has made available
predictive models derived from a range of GTEx tissues. To
compare these, transcriptome imputation methods were
applied to the imputed WTCCC1 data for CD and T1D
using prediction models for GTEx tissues relevant to each
phenotype—EBV-transformed lymphocytes and pancreas
for T1D, and EBV-transformed lymphocytes and sigmoid
colon for CD.
PrediXcan prediction models trained in different GTEx
tissues produced similar sets of results when applied to CD
data (Supplementary Figure S6a), although with less simi-
larity than had been found between applications of different
methods using the same tissue. Although few significant
associations were observed, genes approached significance
on chromosomes 3 and 6 in all tissues. As observed pre-
viously, many differences between results across tissues
could be explained by whether or not genes were tested. For
example, SLC22A5 approached significance in both whole
blood (p= 3.07 × 10−6, β=−0.41) and EBV-transformed
lymphocytes (p= 3.85 × 10−5, β=−0.36), but was not
tested in sigmoid colon. In total, 852 genes were tested
in every tissue and z scores for these genes from each
tissue showed mildly positive correlation (Supplementary
Figure S6c). Likewise, MetaXcan and FUSION found
similar results across different tissues (Supplementary Fig-
ures S7a, S7c, S8a and S8c).
Application of PrediXcan prediction models trained in
different tissues to T1D data also produced sets of similar
results (Supplementary Figure S6b). Significant associations
were observed on chromosomes 6 (C4A, SKIV2L, PSMB9
and BTN3A2 in all tissues) and 12 (RPS26 in all tissues). In
total, 984 genes were tested across all three tissues exam-
ined here. Pairwise correlation between z scores from each
tissue showed positive correlation (Supplementary Figure
S6d). Using prediction models for the same tissues,
MetaXcan and FUSION also found results showing some
similarities and with positive pairwise correlation (Supple-
mentary Figures S7b, S7d, S8b and S8d). In each tissue,
PrediXcan and MetaXcan consistently tested more genes
than FUSION (Table 2), underlining the advantage Pre-
diXcan and MetaXcan hold over FUSION as methods for
discovering potential associations.
We repeated our comparisons of predictive models with
results expected from eQTL statistics across all tissues
tested here, finding that PrediXcan and MetaXcan con-
sistently showed complete agreement with eQTL data
(Aeqtl= 1 for all models), while FUSION models typically
showed weaker agreement (Supplementary Figure S4).
After repeating the process of binning genes according to
the difference between their MetaXcan and FUSION z
scores, higher bins consistently showed lower informativity
for PrediXcan/MetaXcan models across all tissues (Sup-
plementary Figure S2). Genes on chromosome 6 (specifi-
cally the MHC) were found in bin 10 more often than would
be expected if bins were drawn randomly for all
Table 2 Number of genes tested
by each transcriptome
imputation method




Number of genes tested
by both methods




GTEx sigmoid colon 3859 1528 873
GTEx pancreas 4775 1691 1110
J. J. Fryett et al.
tissue–phenotype combinations except CD—EBV-trans-
formed lymphocytes (Supplementary Figure S3).
Comparison of detection ability of transcriptome
imputation methods and GWAS
Transcriptome imputation methods are conceptually similar to
GWAS and have been suggested as a complementary
approach to GWAS. To investigate how these two approaches
compare with respect to detection and localisation of asso-
ciations, we performed standard GWAS on each of the
imputed WTCCC1 CD and T1D data sets. Manhattan plots for
these GWAS are shown in Supplementary Figure S9. Sig-
nificant genes found by transcriptome imputation methods
(most stringent Bonferroni threshold was p < 5.61 × 10−6 for
PrediXcan with DGN prediction models) consistently co-
localised with our observed GWAS hits (genome wide sig-
nificance threshold p < 5 × 10−8). Nine of the 14 loci that
attained genome-wide significance for either CD or T1D
through GWAS showed no significant association signal for
predicted expression. In contrast, only two loci significantly
associated with predicted expression were not identified
through GWAS, implying that transcriptome imputation may
not be as powerful for the discovery of new associations as
GWAS, and reinforcing its role as being complementary to
(rather than a replacement for) GWAS.
Application to CD meta-analysis
We next applied transcriptomic imputation to a larger and
better powered CD data set from a recent meta-analysis [16]
comprising 5956 CD cases and 14,927 controls. As PrediXcan
and MetaXcan showed more agreement with eQTL data and
tested more genes than FUSION, we chose to apply MetaXcan
to these summary statistics. Gene expression prediction mod-
els for relevant GTEx tissues (whole blood, EBV-transformed
lymphocytes and sigmoid colon) were used. In total, 54 unique
predicted expression-trait associations passing genome-wide
significance (p < 5.15 × 10−6) were identified in a range of
genomic loci, with results displayed in Fig. 3 and significant
associations listed in Supplementary Table S3. Of these 54
associations, 27 were predicted associations with gene over-
expression and 27 with underexpression. On average, 92% of
SNPs present in each predictive model were also in the meta-
analysis, suggesting that predictions were accurate. Three of
our detected associations had less than 50% of their prediction
model’s SNPs present in the meta-analysis (FLOT1—whole
blood, FKBPL—whole blood and DDR1—igmoid colon), so
we urge caution when interpreting these results.
We observed 31 associations with predicted whole
blood expression, 13 with EBV-transformed lymphocyte
expression and 10 with sigmoid colon expression. Of our
detected associations, 45 had been suggested previously
in CD GWAS/meta-analysis [1], seven had not been
suggested but were in GWAS risk loci, and two genes
were in loci never before found to be associated with CD
(NPIPB6 and NPIPB7). The most significant association
was with predicted SLC22A5 expression in whole blood
(p= 1.16 × 10−16, β=−0.40), and the association with
the largest predicted effect size was IFRD2 in sigmoid
colon (p= 8.44 × 10−12, β=+ 10.72).
Application to T1D meta-analysis
MetaXcan was also applied to summary statistics from a
recent meta-analysis of T1D [17] with 5913 cases and
Fig. 3 Application of MetaXcan to summary statistics from a meta-analysis of CD using prediction models for three tissues. Manhattan plots
showing p values of predicted expression-trait associations from applications of MetaXcan to summary statistics from a CD meta-analysis using
prediction models trained in a GTEx whole blood data, b GTEx EBV-transformed lymphocytes and c GTEx sigmoid colon. P values are plotted
against the transcription start site for each gene. The red line on each plot shows the Bonferroni-corrected significance threshold at 5.15 × 10−6
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8829 controls, using prediction models trained in GTEx
whole blood, GTEx EBV-transformed lymphocytes and
GTEx pancreas. A total of 154 predicted expression-trait
associations reached genome-wide significance (p <
4.95 × 10−6), consisting of 85 overexpression associations
and 69 underexpression associations. Most prediction
models for significantly associated genes were well
informed, with 74.1% of model SNPs present in the meta-
analysis on average. Predictive models for ten significant
associations (C2, FLOT1, MICA, GABBR1, ZFP57 and
BAK1 in whole blood, and ZFP57, ZSCAN31, PSORS1C1
and MICA in pancreas) had less than 50% of their SNPs in
the meta-analysis, so we interpret these results with
caution. Figure 4 shows Manhattan plots of these results,
with significant associations listed in Supplementary
Table S4.
Sixty-three significant associations were with predicted
whole blood expression, 47 with predicted EBV-
transformed lymphocyte expression and 44 with predicted
pancreas expression, suggesting expression of genes across
each of these tissues may be important in T1D. Significant
associations tended to cluster in risk loci previously impli-
cated in GWAS/meta-analyses of T1D, including the MHC
(119 unique associations, including the 69 most significant
associations) and 12q13.2 (7 unique associations), high-
lighting the importance of these regions in T1D. All but one
(ATP23) of our detected associations had been previously
suggested in a T1D GWAS/meta-analysis or were in a
reported T1D risk locus [1]. The strongest association signal
was with HLA-DRB1 in pancreas, with p= 6.28 × 10−305.
The association with the overall largest effect size (p=
8.04 × 10−106, β=+ 34.36) was with PBX2 expression in
pancreas.
Discussion
Transcriptome imputation has received much attention as a
way of investigating the role of gene expression in complex
disease. In this study, we have compared several tran-
scriptome imputation approaches by applying them to
previously-published GWAS of T1D and CD, and have
shown that they produce similar results. Across the tissues
and phenotypes examined here, we consistently observed
that most predicted expression-trait associations overlapped
with GWAS risk loci, showing the ability of this approach
to identify potential causal genes within established GWAS
risk loci.
Most differences between the methods’ results were due
to different genes being tested. Each method used a dif-
ferent way of selecting which genes to produce models for.
PrediXcan/MetaXcan models were created for all genes
with expression values in GTEx, but only models where the
correlation between predicted and observed expression was
significant at an FDR <5% were uploaded, while FUSION
models were created and uploaded for all genes whose SNP
cis-heritability for gene expression was significant (p <
0.05). As genotype-expression data sets such as GTEx
become larger, the number of genes for which prediction
models can be built will almost certainly increase,
improving the coverage of these methods.
We showed that for genes where the different methods
disagreed most, a small number of SNPs in the prediction
model used by PrediXcan and MetaXcan were missing from
the GWAS data. For PrediXcan and MetaXcan, SNPs
missing from the GWAS data set but in the predictive
models are ignored during prediction. However, FUSION
uses the ImpG-summary algorithm to impute summary
Fig. 4 Application of MetaXcan to summary statistics from a meta-analysis of T1D using prediction models for three tissues. Manhattan plots
showing p values of predicted expression-trait associations from applications of MetaXcan to summary statistics from a meta-analysis of T1D
using prediction models trained in a GTEx whole blood data, b GTEx EBV-transformed lymphocytes and c GTEx pancreas. P values are plotted
against the transcription start site for each gene. The red line on each plot shows the Bonferroni-corrected significance threshold at 5.01 × 10−6
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statistics for these missing GWAS SNPs. While this may
appear attractive, the GWAS SNPs were missing because
they failed our post-imputation quality-control procedures,
meaning FUSION’s imputation of these SNPs’ summary
statistics likely has a high degree of uncertainty. For this
reason, we believe PrediXcan and MetaXcan to be more
compelling as their predictions are based only on the most
reliable SNPs. Close attention should be paid to the pro-
portion of a model’s SNPs that are present in the GWAS (or
imputed GWAS) data for all methods.
By applying transcriptome imputation methods using
prediction models for different tissues, we found that results
were broadly similar across tissues, but with some crucial
differences. Genetic regulation of gene expression is
thought to be similar across GTEx tissues [13, 24], so it is
reassuring to see our results recapitulate this. For this reason
it is also likely that associations would be found even in
tissues with little biological relevance to the phenotype of
interest. We observed that many genes are tested across
multiple tissues, raising the possibility of multivariate test-
ing of gene expression incorporating tissue-tissue correla-
tion. Multivariate testing is available (or being developed)
in both the MetaXcan and the FUSION packages, and could
improve power to detect genes whose expression is con-
sistently associated with a phenotype across tissues.
We compared transcriptome imputation methods to the
standard GWAS approach, finding that most significant
associations occurred close to GWAS loci, implying that
transcriptome imputation approaches are unlikely to detect
many 'new' associations. However, by identifying potentially
causal genes within each GWAS risk locus, transcriptome
imputation still presents a useful complementary method to
GWAS to aid downstream biological interpretation.
Throughout our investigations, PrediXcan and MetaXcan
were consistently seen to be more robust than FUSION.
First, comparison of predictive models used by each method
with eQTL statistics from GTEx revealed that PrediXcan/
MetaXcan models repeatedly showed better agreement with
eQTLs than FUSION. Second, PrediXcan/MetaXcan mod-
els tended to predict expression slightly more accurately
than FUSION models when applied to data from the Geu-
vadis project. Third, FUSION’s imputation of summary
statistics for missing SNPs may result in predictions with
low certainty. For these reasons, we chose to use MetaXcan
for subsequent analyses.
We applied MetaXcan to summary statistics from a meta-
analysis of CD, finding 54 associations between predicted
gene expression and disease status. These included genes
previously known to be associated with CD (SLC22A5,
IRGM and ATG16L1), and genes that have never before
been suggested (NPIPB6 and NPIPB7). NPIPB6 and
NPIPB7 are nuclear pore complex-interacting genes, how-
ever little else is known about them and further study is
required to determine if a true causal role in CD is likely.
Other interesting associations include ETS2 and ICAM1,
whose expression has been previously implicated in CD
[25, 26]. A recent application of FUSION to the same CD
summary statistics found similar results to those shown here
[12], showing that similarities between transcriptome
imputation approaches are not unique to the WTCCC1 data.
Furthermore, SNPs near 34 of the 54 significant genes were
found by 4C-seq to interact with DNA regulatory elements
[27], underlining the potential role of genetically deter-
mined expression of these genes in CD.
Finally, we applied MetaXcan to summary statistics from
a meta-analysis of T1D, finding 154 predicted expression-
trait associations, including one (ATP23) mapping outside
of known T1D risk loci. ATP23 is thought to be involved in
the repair of DNA double-strand breaks (DSBs), and further
investigation of this finding is required to understand its
potential role in T1D. Most of the other associations
(including the 69 with strongest association signals) were
with genes in the MHC. While associations in the MHC
tend to be attributed to coding variation, it is also possible
that this coding variation is in high linkage disequilibrium
with regulatory variation that affects expression of genes
involved in immunity. Due to the complex structure of
linkage disequilibrium in the MHC, disentangling these
possibilities is difficult, and more detailed investigation will
be required. It is also possible that this complex structure of
linkage disequilibrium and the large effect sizes typically
seen in the MHC for T1D may have led to a number of
spurious associations.
In conclusion, we have confirmed that transcriptome
imputation is a powerful approach for interpreting the
results of GWAS and identifying causal genes in common
and complex diseases. We have shown that the current
methods for transcriptomic imputation perform similarly,
although PrediXcan and MetaXcan appear to be the most
robust. These approaches will be crucial for helping in the
interpretation of GWAS results, and thus in the successful
identification of future therapies for a range of complex
diseases. It is likely that transcriptome imputation will
become even more useful as improvements are made to
each method and to genotype-expression reference panels.
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